PURE RED CELL APLASIA INDUCED BY ERYTHROPOIETIN

Introduction: Recombined human erythropoietin has been present in clinical practice for more than 20 years, in these therapeutic indications: anemia in kidney insufficiency, anemia during chemotherapy of tumors, prevention of anemias that appear in premature born babies, it is used for increasing au...

Full description

Bibliographic Details
Main Authors: MIhajlovic Filip, Milosavljevic Aleksandar, Djuric Dusan
Format: Article
Language:English
Published: Association of medical doctors Sanamed Novi Pazar 2018-05-01
Series:Sanamed
Subjects:
Online Access:http://www.sanamed.rs/OJS/index.php/Sanamed/article/view/197/106
_version_ 1827334668000690176
author MIhajlovic Filip
Milosavljevic Aleksandar
Djuric Dusan
author_facet MIhajlovic Filip
Milosavljevic Aleksandar
Djuric Dusan
author_sort MIhajlovic Filip
collection DOAJ
description Introduction: Recombined human erythropoietin has been present in clinical practice for more than 20 years, in these therapeutic indications: anemia in kidney insufficiency, anemia during chemotherapy of tumors, prevention of anemias that appear in premature born babies, it is used for increasing autologous blood cell levels before blood transfusion, AIDS joined anemia (intensified by zidovudine), anemia joined with chronic inflammatory conditions such as rheumatoid arthritis(still in research phase). During the course of Erythropoietin treatment side effects have been noticed, that include multiple organ systems, and have different levels of frequency. Major number of studies shows connection between erythropoietin treatment and bone marrow aplasia, but small number of them states clearly defined side-effect that explains this phenomenon. Objective: Goal of this paper is to analyze available case studies of bone marrow aplasia during erythropoietin application, access their quality and causality of every study. Method: Research of literature used for the preparation of this systematic review has been conducted during the period of November- December 2017. In search for literature medical base PubMed has been used. Inclusion criteria were: available full article, publications in English language, publications conducted on humans, and case report studies. Eight studies passed selection. Results: results were presented by 5 charts: documentation size, credibility, number of case study reports of side-effects in the paper that was graded, Naranjo causality score, data extraction chart. Mean grade value of the studies quality was 7,0, while mean Naranjo score was 6,6.
first_indexed 2024-03-07T18:00:02Z
format Article
id doaj.art-c2daee3bcdd74a87a4bb79e79b305477
institution Directory Open Access Journal
issn 1452-662X
2217-8171
language English
last_indexed 2024-03-07T18:00:02Z
publishDate 2018-05-01
publisher Association of medical doctors Sanamed Novi Pazar
record_format Article
series Sanamed
spelling doaj.art-c2daee3bcdd74a87a4bb79e79b3054772024-03-02T11:06:18ZengAssociation of medical doctors Sanamed Novi PazarSanamed1452-662X2217-81712018-05-01131616810.24125/sanamed.v13i1.197PURE RED CELL APLASIA INDUCED BY ERYTHROPOIETINMIhajlovic Filip0Milosavljevic Aleksandar1Djuric Dusan2 Faculty of medical sciences, University of Kragujevac, SerbiaFaculty of medical sciences, University of Kragujevac, SerbiaFaculty of medical sciences, University of Kragujevac, SerbiaIntroduction: Recombined human erythropoietin has been present in clinical practice for more than 20 years, in these therapeutic indications: anemia in kidney insufficiency, anemia during chemotherapy of tumors, prevention of anemias that appear in premature born babies, it is used for increasing autologous blood cell levels before blood transfusion, AIDS joined anemia (intensified by zidovudine), anemia joined with chronic inflammatory conditions such as rheumatoid arthritis(still in research phase). During the course of Erythropoietin treatment side effects have been noticed, that include multiple organ systems, and have different levels of frequency. Major number of studies shows connection between erythropoietin treatment and bone marrow aplasia, but small number of them states clearly defined side-effect that explains this phenomenon. Objective: Goal of this paper is to analyze available case studies of bone marrow aplasia during erythropoietin application, access their quality and causality of every study. Method: Research of literature used for the preparation of this systematic review has been conducted during the period of November- December 2017. In search for literature medical base PubMed has been used. Inclusion criteria were: available full article, publications in English language, publications conducted on humans, and case report studies. Eight studies passed selection. Results: results were presented by 5 charts: documentation size, credibility, number of case study reports of side-effects in the paper that was graded, Naranjo causality score, data extraction chart. Mean grade value of the studies quality was 7,0, while mean Naranjo score was 6,6.http://www.sanamed.rs/OJS/index.php/Sanamed/article/view/197/106erythropoietin side effectsanti-erythropoietin antibodiespure red cell aplasia.
spellingShingle MIhajlovic Filip
Milosavljevic Aleksandar
Djuric Dusan
PURE RED CELL APLASIA INDUCED BY ERYTHROPOIETIN
Sanamed
erythropoietin side effects
anti-erythropoietin antibodies
pure red cell aplasia.
title PURE RED CELL APLASIA INDUCED BY ERYTHROPOIETIN
title_full PURE RED CELL APLASIA INDUCED BY ERYTHROPOIETIN
title_fullStr PURE RED CELL APLASIA INDUCED BY ERYTHROPOIETIN
title_full_unstemmed PURE RED CELL APLASIA INDUCED BY ERYTHROPOIETIN
title_short PURE RED CELL APLASIA INDUCED BY ERYTHROPOIETIN
title_sort pure red cell aplasia induced by erythropoietin
topic erythropoietin side effects
anti-erythropoietin antibodies
pure red cell aplasia.
url http://www.sanamed.rs/OJS/index.php/Sanamed/article/view/197/106
work_keys_str_mv AT mihajlovicfilip pureredcellaplasiainducedbyerythropoietin
AT milosavljevicaleksandar pureredcellaplasiainducedbyerythropoietin
AT djuricdusan pureredcellaplasiainducedbyerythropoietin